AU2953699A - Novel polymorphic forms of an antidiabetic agent: process for their preparation and a pharmaceutical composition containing them - Google Patents
Novel polymorphic forms of an antidiabetic agent: process for their preparation and a pharmaceutical composition containing themInfo
- Publication number
- AU2953699A AU2953699A AU29536/99A AU2953699A AU2953699A AU 2953699 A AU2953699 A AU 2953699A AU 29536/99 A AU29536/99 A AU 29536/99A AU 2953699 A AU2953699 A AU 2953699A AU 2953699 A AU2953699 A AU 2953699A
- Authority
- AU
- Australia
- Prior art keywords
- preparation
- pharmaceutical composition
- composition containing
- polymorphic forms
- antidiabetic agent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
- C07D265/34—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings
- C07D265/38—[b, e]-condensed with two six-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
- C07C279/04—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton
- C07C279/14—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton being further substituted by carboxyl groups
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/IB1999/000681 WO2000063191A1 (en) | 1999-04-16 | 1999-04-16 | Novel polymorphic forms of an antidiabetic agent: process for their preparation and a pharmaceutical composition containing them |
Publications (1)
Publication Number | Publication Date |
---|---|
AU2953699A true AU2953699A (en) | 2000-11-02 |
Family
ID=11004846
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU29536/99A Abandoned AU2953699A (en) | 1999-04-16 | 1999-04-16 | Novel polymorphic forms of an antidiabetic agent: process for their preparation and a pharmaceutical composition containing them |
Country Status (3)
Country | Link |
---|---|
JP (1) | JP2003508348A (en) |
AU (1) | AU2953699A (en) |
WO (1) | WO2000063191A1 (en) |
Families Citing this family (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE309818T1 (en) | 2000-03-08 | 2005-12-15 | Novo Nordisk As | LOWERING SERUM CHOLESTEROL |
US6897199B2 (en) * | 2001-02-05 | 2005-05-24 | Dr. Reddy's Laboratories Ltd. | Pharmaceutically acceptable salts of phenoxazine and phenothiazine compounds |
EP2243776A1 (en) | 2001-10-12 | 2010-10-27 | High Point Pharmaceuticals, LLC | Substituted piperidines and their use for the treatment of diseases related to the histamine H3 receptor |
KR101018318B1 (en) | 2001-12-21 | 2011-03-04 | 노보 노르디스크 에이/에스 | Amide derivatives as gk activators |
EP1531815B1 (en) | 2002-06-27 | 2014-09-24 | Novo Nordisk A/S | Glucokinase activators |
EP1625112B1 (en) | 2003-05-14 | 2009-07-22 | High Point Pharmaceuticals, LLC | Novel compounds for treatment of obesity |
BRPI0414890A (en) | 2003-09-30 | 2006-12-12 | Novo Nordisk As | compound, methods of retarding the progression of igt to type 2 diabetes, and type 2 diabetes to insulin-requiring diabetes, to treat obesity or prevent overweight, to regulate appetite, to induce satiety, to prevent weight gain. weight, increasing energy expenditure, and treating a disease or condition, pharmaceutical composition, and use of a compound |
JP4865565B2 (en) | 2003-12-09 | 2012-02-01 | ノヴォ ノルディスク アー/エス | Controlling food selection using GLP-1 agonists |
EP2444397A1 (en) | 2004-01-06 | 2012-04-25 | Novo Nordisk A/S | Heteroaryl-ureas and their use as glucokinase activators |
US20080113944A1 (en) | 2004-05-04 | 2008-05-15 | Novo Nordisk A/S | Novel Indole Derivatives |
CN1950078A (en) | 2004-06-11 | 2007-04-18 | 诺和诺德公司 | Counteracting drug-induced obesity using glp-1 agonists |
US8263551B2 (en) | 2004-11-22 | 2012-09-11 | Novo Nordisk A/S | Soluble, stable insulin-containing formulations with a protamine salt |
WO2006058923A1 (en) | 2004-12-03 | 2006-06-08 | Novo Nordisk A/S | Heteroaromatic glucokinase activators |
ATE536344T1 (en) | 2005-07-04 | 2011-12-15 | High Point Pharmaceuticals Llc | HISTAMINE H3 RECEPTOR ANTAGONISTS |
BRPI0612996A2 (en) | 2005-07-14 | 2010-12-14 | Novo Nordisk As | urea glucokinase activators |
ES2426345T3 (en) | 2005-07-20 | 2013-10-22 | Eli Lilly And Company | Compound bound in 1-amino position |
AU2006342449B2 (en) | 2005-11-17 | 2012-03-01 | Eli Lilly And Company | Glucagon receptor antagonists, preparation and therapeutic uses |
MX2008011123A (en) | 2006-03-28 | 2008-09-30 | High Point Pharmaceuticals Llc | Benzothiazoles having histamine h3 receptor activity. |
MX2008014766A (en) | 2006-05-29 | 2009-03-06 | High Point Pharmaceuticals Llc | 3- (1, 3-benz0di0x0l-5-yl) -6- (4-cyclopropylpiperazin-1-yl) -pyridazine, its salts and solvates and its use as histamine h3 receptor antagonist. |
WO2008059026A1 (en) | 2006-11-15 | 2008-05-22 | High Point Pharmaceuticals, Llc | Novel 2-(2-hydroxyphenyl)benzimidazoles useful for treating obesity and diabetes |
EP2086951B1 (en) | 2006-11-15 | 2011-12-21 | High Point Pharmaceuticals, LLC | Novel 2-(2-hydroxyphenyl) benzothiadiazines useful for treating obesity and diabetes |
EP2099777B1 (en) | 2007-01-11 | 2015-08-12 | Novo Nordisk A/S | Urea glucokinase activators |
WO2011104378A1 (en) | 2010-02-26 | 2011-09-01 | Novo Nordisk A/S | Peptides for treatment of obesity |
BR112012021231A2 (en) | 2010-02-26 | 2015-09-08 | Basf Plant Science Co Gmbh | method for enhancing plant yield, plant, construct, use of a construct, method for producing a transgenic plant, collectable parts of a plant, products derived from a plant, use of a nucleic acid and method for producing a product |
EP2552950A1 (en) | 2010-03-26 | 2013-02-06 | Novo Nordisk A/S | Novel glucagon analogues |
EP2670368A4 (en) | 2011-02-03 | 2015-04-15 | Pharmedica Ltd | New oral dissolving films for insulin administration, for treating diabetes |
MX2013011175A (en) | 2011-03-28 | 2013-11-01 | Novo Nordisk As | Novel glucagon analogues. |
IN2014CN02448A (en) | 2011-09-23 | 2015-06-19 | Novo Nordisk As | |
WO2013082106A1 (en) | 2011-12-02 | 2013-06-06 | The General Hospital Corporation | Differentiation into brown adipocytes |
RS59124B1 (en) | 2013-04-18 | 2019-09-30 | Novo Nordisk As | Stable, protracted glp-1/glucagon receptor co-agonists for medical use |
WO2015185640A1 (en) | 2014-06-04 | 2015-12-10 | Novo Nordisk A/S | Glp-1/glucagon receptor co-agonists for medical use |
CN111032680A (en) | 2017-03-15 | 2020-04-17 | 诺和诺德股份有限公司 | Bicyclic compounds capable of binding to melanocortin 4 receptor |
US20210221867A1 (en) | 2018-05-15 | 2021-07-22 | Novo Nordisk A/S | Compounds Capable of Binding to Melanocortin 4 Receptor |
WO2020053414A1 (en) | 2018-09-14 | 2020-03-19 | Novo Nordisk A/S | Bicyclic compounds capable of acting as melanocortin 4 receptor agonists |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5248699A (en) * | 1992-08-13 | 1993-09-28 | Pfizer Inc. | Sertraline polymorph |
IN182496B (en) * | 1996-02-20 | 1999-04-17 | Reddy Research Foundation | |
FR2746099B1 (en) * | 1996-03-13 | 1998-04-30 | IMPROVED PROCESS FOR THE PREPARATION OF 3- (10-PHENOTHIAZYL) -PROPANOIC OR 3- (10-PHENOXAZYL) -PROPANOIC ACID DERIVATIVES | |
CN1196730A (en) * | 1996-06-19 | 1998-10-21 | 雷迪博士研究基金会 | Novel polymorphic forms of troglitazone having enhanced anti-brabetic activity and process for their preparation |
WO1999019313A1 (en) * | 1997-10-27 | 1999-04-22 | Dr. Reddy's Research Foundation | Novel tricyclic compounds and their use in medicine; process for their preparation and pharmaceutical compositions containing them |
WO1999038850A1 (en) * | 1998-01-29 | 1999-08-05 | Dr. Reddy's Research Foundation | Novel alkanoic acids and their use in medicine, process for their preparation and pharmaceutical compositions containing them |
-
1999
- 1999-04-16 WO PCT/IB1999/000681 patent/WO2000063191A1/en active Application Filing
- 1999-04-16 AU AU29536/99A patent/AU2953699A/en not_active Abandoned
-
2000
- 2000-04-17 JP JP2000612284A patent/JP2003508348A/en active Pending
Also Published As
Publication number | Publication date |
---|---|
WO2000063191A1 (en) | 2000-10-26 |
JP2003508348A (en) | 2003-03-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU4465200A (en) | Novel polymorphic forms of an antidiabetic agent: process for their preparation and a pharmaceutical composition containing them | |
AU2953699A (en) | Novel polymorphic forms of an antidiabetic agent: process for their preparation and a pharmaceutical composition containing them | |
HUP0200758A3 (en) | Novel polymorphic forms of an antidiabetic agent: process for their preparation and pharmaceutical compositions containing them | |
HUP0003844A3 (en) | Novel spiroazabicyclic heterocyclic compounds, process for their preparation, their use and pharmaceutical compositions containing them | |
HUP0204245A3 (en) | Novel n-azabicyclo-amide derivatives, process for their preparation, pharmaceutical compositions containing them and their use | |
AU4949800A (en) | 2-arylpurine-9-acetamide derivatives, process for the preparation thereof, medicinal compositions containing the same and intermediates of the derivatives | |
HUP9801045A3 (en) | Sulfonyl-amino-carboxylic acid derivatives, use thereof, pharmaceutical compositions containing them and process for their preparation | |
HUP0102307A3 (en) | Bispidine derivatives, process for their preparation, pharmaceutical compositions thereof and intermediates | |
HUP0202103A2 (en) | 8-phenyl-6,9-dihydro-[1,2,4]triazolo[3,4-i]purin-5-one derivatives, their use, pharmaceutical compositions containing them, process for the preparation of the compounds and intermediates | |
HUP0203183A3 (en) | Novel heterocyclic compounds, process for their preparation and pharmaceutical compositions containing them and their use | |
HUP9801044A3 (en) | Sulfonylamino-carboxylic acid derivatives, process for their preparation, their use and pharmaceutical compositions containing them | |
HUP0203559A3 (en) | Polymorphic forms of sertraline hydrochloride, process for their preparation and pharmaceutical compositions containing them | |
HUP0105108A3 (en) | Amide compounds, process for their preparation and pharmaceutical compositions containing them | |
AU2001258677A1 (en) | Novel compounds having antiinflammatory activity: process for their preparation and pharmaceutical compositions containing them | |
HUP0003053A3 (en) | Crystalline forms of 33-epichloro-33-desoxyascomycin, process for their preparation and pharmaceutical compositions containing them | |
EG22344A (en) | Process for preparing of novel pharmaceutical composition | |
AU8031598A (en) | 3-aminoindane derivatives, process for their preparation and pharmaceutical compositions containing them | |
HUP0100019A3 (en) | Novel polymorphic forms of cipamfylline, process for their preparation and pharmaceutical compositions thereof | |
HUP0201146A3 (en) | Halo derivatives of 9-deoxo-9a-aza-9a-homerythromycin a, process for their preparation and pharmaceutical compositions containing them | |
HUP0102830A3 (en) | Antidiabetic piperazine derivatives, process for their preparation and pharmaceutical compositions containing them | |
IL147069A0 (en) | Novel benzene derivatives, a process for their preparation and pharmaceutical compositions containing them | |
AU5525199A (en) | N-hydroxyacylamino compounds, process for their preparation and pharmaceutical compositions containing them | |
HU9803017D0 (en) | New heterocyclic compounds, a process for their preparation and pharmaceutical compositions containing them | |
IL148164A0 (en) | Pharmaceutical compositions containing thiazolidinedione derivatives and process for their preparation | |
HUP0001712A2 (en) | 2,3-methano-amino acid derivatives, a process for their preparation and pharmaceutical compositions containing them |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MK6 | Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase |